ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
go to the article

go back to the homepage

  • Subscription
  • Newsletter
  • Advertise
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Corporate publications
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ADVERTISEMENT

Bayer Pharmaceuticals headquarters in BerlinBayer AG
Bayer

Bayer rebuilds pharma while waiting for Monsanto relief

A stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation. more ➔

Protein design center of Wuxi AppTec in Gräfelfing close to Munich. Will become the global center of excellence for drug discoveryWuxi AppTec
China

WuXi AppTec bets on expansion in Europe

Global science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues … more ➔

ADVERTISEMENT

Wales Millennium Centre, Bute Place, Cardiff, UK.
fundraising

Draig raises $65M Series B as depression trials advance

Welsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million little more than a year after emerging … more ➔

aerial view barcelona spain
investment

CriteriaCaixa targets €300M for biotech and tech by 2030

Spanish investment holding company CriteriaCaixa plans to invest €300m in early-stage biotechnology and technology companies by 2030 through its two specialist venture funds. more ➔

exploding cells colors
Technology

Targeted Protein Degradation: Designed to destroy

Targeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting … more ➔

European Biotechnology

1 / 4
EBM 2026_cover

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo
2 / 4
10/3/26 mw: Satz, PDF an JE, danach zu Andi

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo
3 / 4
EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo
4 / 4
EB325_cover

Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China … more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI
european-biotechnology-logo

NEWSLETTER


Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.


Subscribe to our free newsletter!Subscribe here

Back pain
fundraising

PharmNovo raises €3.5M for phase 2 pain trial

Swedish biotech PharmNovo has raised about SEK39m (€3.5m) to help finance a phase 2 study of PN6047, its experimental treatment for neuropathic pain. more ➔

cutting wood axe
Strategy

AB Science cuts three trials in pipeline reset

French biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leu … more ➔

ADVERTISEMENT

Sponsored Publications

indivumed_beide_960x540-705x397
Indivumed

Indivumed, ready to set sail to the clinic

With the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the … more ➔

APPOINTMENTS

all appointments

EB.com_ariane-de-ganck-phd-cso-ardenaArdena
Ardena

Seasoned CSO takes the helm

Ariane de Ganck, PhD, took over the position as new Chief Scientific Officer (CSO) at Ardena. She started in 2019 at the Ghent-based …
more ➔

EB.com_Ida_Nordberg_CFO_PeptiSystemsPeptiSystems AB
PeptiSystems AB

New CFO to Drive Commercial Growth

Swedish life science company PeptiSystems has appointed Ida Nordberg as Chief Financial Officer (CFO). The appointment marks another …
more ➔

EB.com_Russell-thomasSymeres
Symeres/Axxam

One CSO for two companies

With the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. …
more ➔

EB.com_Olav_Hellebo_neuExonate, Ltd.
Exonate Ltd.

Experienced CEO takes over

By appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development …
more ➔

crumbled paper
partnering

Roche drops two Huntington’s programmes from Ionis

Roche has discontinued two Huntington’s disease programmes after its Ionis-partnered drug tominersen failed to improve patients’ symptoms and a separate candidate raised concerns in animal studi … more ➔

ADVERTISEMENT

red light wrosswalk
clinical trial

AstraZeneca and Ionis miss in key ATTR-CM trial

AstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy … more ➔

goodbye sign on a desk
licensing

GSK ends Alector neuroscience deal after trial failures

GSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks. more ➔

All news
newsletter_link

EVENT


European Biotech Magazine 960x540px
July 21 - July 23in Amsterdam, Netherlands

Join the only Neoantigen-Specific Summit this July

The 9th International Neoantigen Summit returns to Amsterdam to bring together the only dedicated forum for end-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this is your only platform dedicated to sharing critical developments in neoantigen the ... ➔

Knowbio GmbH
  • Link to LinkedIn
  • Link to Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top Scroll to top Scroll to top